A preclinical study using myeloma demonstrated that adenovirus‐mediated delivery of WT TP53 can potently induce apoptosis.[27] Our current study also suggests that delivery of WT TP53 and inhibition of NEK2 in a TP53−/− MM cell line can suppress tumor formation and enhance BTZ's therapeutic effect. This evidence concerns the gene NEK2 and neoplasm.